Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease by Becker-Grünig, Tabea et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2013
Efficacy of exercise training in pulmonary arterial hypertension associated
with congenital heart disease
Becker-Grünig, Tabea; Klose, Hans; Ehlken, Nicola; Lichtblau, Mona; Nagel, Christian; Fischer,
Christine; Gorenflo, Matthias; Tiede, Henning; Schranz, Dietmar; Hager, Alfred; Kaemmerer, Harald;
Miera, Oliver; Ulrich, Silvia; Speich, Rudolf; Uiker, Sören; Grünig, Ekkehard
Abstract: BACKGROUND: The objective of this prospective study was to assess the efficacy of exercise
training as add-on to medical therapy in patients with congenital heart disease associated pulmonary ar-
terial hypertension (CHD-APAH). METHODS: Patients with invasively confirmed CHD-APAH received
in-hospital exercise training for 3weeks and continued at home. Efficacy parameters were evaluated at
baseline, after 3 and 15weeks. Medical treatment remained unchanged. Worsening events and survival
rate were assessed in a follow-up period of 21±14months. RESULTS: Twenty consecutive CHD-APAH
patients (16 female, 4 male, mean pulmonary arterial pressure 60±23mmHg) were included. Patients
significantly improved the mean distance walked in 6min compared to baseline by 63±47m after 3weeks
(p<0.001) and by 67±59m after 15weeks (p=0.001). Quality of life-score (p=0.05), peak oxygen con-
sumption (p=0.002) and maximal workload (p=0.003) improved significantly by exercise training after
15weeks. The 1- and 2-year survival rates were 100%, the transplantation-free survival rate was 100%
after 1year and 93% after 2years. CONCLUSION: Exercise training as add-on to medical therapy may
be effective in patients with CHD-APAH and improved work capacity, quality of life and further prog-
nostic relevant parameters. It was associated with an excellent long-term survival. Further randomized
controlled studies are needed to confirm these results.
DOI: 10.1016/j.ijcard.2012.09.036
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-69347
Accepted Version
Originally published at:
Becker-Grünig, Tabea; Klose, Hans; Ehlken, Nicola; Lichtblau, Mona; Nagel, Christian; Fischer, Chris-
tine; Gorenflo, Matthias; Tiede, Henning; Schranz, Dietmar; Hager, Alfred; Kaemmerer, Harald; Miera,
Oliver; Ulrich, Silvia; Speich, Rudolf; Uiker, Sören; Grünig, Ekkehard (2013). Efficacy of exercise train-
ing in pulmonary arterial hypertension associated with congenital heart disease. International Journal of
Cardiology, 168(1):375-381. DOI: 10.1016/j.ijcard.2012.09.036
 1
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
Efficacy of Exercise Training in Pulmonary Arterial Hypertension 
associated with Congenital Heart Disease 
Tabea Becker-Grünig1*, Hans Klose, MD9*; Nicola Ehlken, BSc1, Mona Lichtblau1, 
Christian Nagel, MD1; Christine Fischer, PhD2; Matthias Gorenflo, MD3; Henning 
Tiede, MD4; Dietmar Schranz, MD5; Alfred Hager, MD6; Harald Kaemmerer, MD6; 
Oliver Miera, MD7; Silvia Ulrich, MD8; Rudolf Speich, MD8; Sören Uiker, MD10; 
Ekkehard Grünig, MD1.  
*equally contributed; All authors take responsibility for all aspects of the reliability and 
freedom from bias of the data presented and their discussed interpretation. 
 
Centre for Pulmonary Hypertension at Thoraxclinic Heidelberg1, Institute of Human 
Genetics2, Department of Pediatric Cardiology3, University of Heidelberg, Germany. 
Department of Pneumology4 and Paediatric Cardiology5, University of Giessen, 
Germany. 
Clinic of Pediatric Cardiology and Congenital Heart Defects6, Munich, Germany. 
Department of Congenital Heart Disease, German Heart Center Berlin7, Germany. 
Centre for Pulmonary Hypertension, University Hospital Zurich8, Switzerland. 
Department of Pneumology, University of Hamburg-Eppendorf9, Hamburg, Germany. 
Rehabilitation Clinic Heidelberg Koenigstuhl, Heidelberg, Germany10.  
 
Corresponding Author:  
  Ekkehard Grünig, MD 
  Centre for Pulmonary Hypertension Thoraxclinic 
  University Hospital Heidelberg 
  Amalienstrasse 5, D-69126 Heidelberg  
  Tel: +49-6221-396-8053, Fax: +49-6221-398-1209 
  E-Mail: ekkehard.gruenig@thoraxklinik-heidelberg.de 27 
28 
29 
30 
31 
32 
The study was funded by a grant of the German Pulmonary Hypertension 
Association; Pulmonale Hypertonie e.V., Rheinstetten, Germany. None of the authors 
has a conflict of interest.  
Key words: Pulmonary Hypertension, Rehabilitation, Exercise Training, Congenital 
Heart Disease  
 2
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
Structured Abstract 
Background: The objective of this prospective study was to assess the efficacy of 
exercise training as add-on to medical therapy in patients with congenital heart 
disease associated pulmonary arterial hypertension (CHD-APAH). 
Methods: Patients with invasively confirmed CHD-APAH received in-hospital 
exercise training for 3 weeks and continued at home. Efficacy parameters were 
evaluated at baseline, after 3 and 15 weeks. Medical treatment remained unchanged. 
Worsening events and survival rate were assessed in a follow-up period of 21±14 
months. 
Results: Twenty consecutive CHD-APAH patients (16 female, 4 male, mean 
pulmonary arterial pressure 60±23mmHg) were included. Patients significantly 
improved the mean distance walked in 6 minutes compared to baseline by 63±47 
meters after 3 weeks (p<0.001) and by 67±59 meters after 15 weeks (p=0.001). 
Quality of life-score (p=0.05), peak oxygen consumption (p=0.002) and maximal 
workload (p=0.003) improved significantly by exercise training after 15 weeks. The 1- 
and 2 year survival rates were 100%, the transplantation-free survival rate was 100% 
after 1 year and 92% after 2 years.  
Conclusion: Exercise training as add-on to medical therapy may be effective in 
patients with CHD-APAH and improved work capacity, quality of life and further 
prognostic relevant parameters. It was associated with an excellent long-term 
survival. Further randomized controlled studies are needed to confirm these results. 
 Words count: 209 
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Introduction 
Congenital heart disease- associated pulmonary arterial hypertension (CHD-APAH) 
is an important subgroup of associated PAH (APAH) which accounts for 
approximately 11% of all patients with PAH [1]. In about 0.8-1 of 1000 live births 
relevant CHD has been diagnosed. Today, in Western countries more than 90% of 
these children reach adulthood, in some cases with significant pulmonary vascular 
disease [2]. The prevalence of APAH in CHD in Germany is not known. European 
registry data suggest a prevalence of APAH in about 4-10% of adult CHD-patients [1, 
3, 4]; up to 25-50% develop an Eisenmenger Syndrome (ES) [5]. Patients with CHD-
APAH had identical histological findings as idiopathic PAH (IPAH) [6] and revealed a 
markedly reduced exercise capacity and quality of life [4, 7]. ES had the worst 
exercise capacity compared to other forms of CHD-APAH [7]. All-cause mortality risk 
was more than 2-fold higher for CHD-patients with APAH compared with those 
without [8]. Estimated 1-, 2-, and 3-year survival rates in CHD-APAH-patients were 
97%, 89% and 77%, respectively [9]. 
In contrast to IPAH, only few randomized controlled trials on advanced, disease-16 
targeted medical therapy have been performed in CHD-APAH including drugs as 17 
Bosentan (BREATHE-5 study) [5] and Tadalafil [10] showing significant 18 
improvements of pulmonary hemodynamics and exercise tolerance. Positive effects 19 
for exercise capacity were also described for sildenafil, epoprostenol and 20 
ambrisentan in small, uncontrolled studies [10-13] . Only few data are available on 21 
combination therapies, including 2 to or more PAH-targeted drugs [14-16]. However, 22 
the effect of advanced medical therapy on exercise capacity and quality of life seems 23 
to be very limited in this subgroup. Thus, especially patients with CHD-APAH may 24 
need additional therapeutic tools addressing their exercise capacity and quality of 25 
life. It is unclear whether and to which extend CHD or CHD-APAH-patients should 26 
 4
perform sports or exercise training, especially with respect that their hypoxemia 1 
usually rapidly deteriorates during exercise. In patients with IPAH and other forms of 2 
APAH exercise training as add-on to optimized medical treatment has been shown to 3 
increase exercise capacity, quality of life, peak oxygen consumption, WHO-functional 4 
class (WHO-FC) in a randomized, controlled study [17] and in single arm studies [18-5 
20] and possibly improved clinical outcome [19]. There are only few small 6 
uncontrolled studies showing a benefit of exercise training for exercise capacity in 7 
CHD-patients without PAH [21-23]. Except one report with 4 CHD-APAH-patients 8 
receiving rehabilitation [24] up to now there is no study focusing on the acute and 9 
long-term effect of exercise training in this cohort. The aim of this study was to 10 
prospectively assess the effects of exercise training on safety and prognostic 11 
relevant factors such as exercise capacity and quality of life in a cohort of patients 12 
with severe CHD-APAH and to analyze the 1- and 2 year survival rates.  13 
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Methods 
Study Population and Design  
This prospective study included adult patients with invasively confirmed severe 
chronic CHD-APAH, being stable under disease-targeted medication, who received 
exercise and respiratory training between September 2008 and October 2011. 
Patients had to be under optimized advanced medical therapy for PAH (as 
endothelin-antagonists, inhaled prostanoids, phosphodiesterase-5-inhibitors, 
diuretics and if useful, supplemental oxygen) for at least 2 months before entering the 
study. Those with PAH who were newly diagnosed had an interval of at least 6 
months between initiation of a new PAH-targeted medical treatment and the start of 
exercise training. Medication remained unchanged during the study period from 
baseline to 15 weeks. The diagnosis “CHD-APAH” was established at the 
participating PH centers according to current guidelines [25, 26]. CHD had been 
confirmed by specialized centers for congenital heart diseases in each patient. All 
patients starting the rehabilitation program gave written informed consent for this 
study and the study protocol conforms to the ethical guidelines of the 1975 
Declaration of Helsinki as reflected in a priori approval by the Ethics Committee of 
the University of Heidelberg.  
 
Outcome Measures 
At baseline, after 3 weeks and 15 weeks efficacy parameters were prospectively 
evaluated as previously described [17, 19]. 6-minute walking distance (6MWD) was 
carried out under standardized conditions. Cardiopulmonary exercise testing and 
stress-Doppler echocardiography were carried out during supine bicycle exercise as 
described previously [17]. Workload, heart rate, systolic pulmonary artery pressure 
(sPAP), systolic (RRsys) and diastolic (RRdias) systemic blood pressures, ventilation 
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(VE), oxygen uptake (VO2), oxygen pulse (VO2/heart rate), and carbon dioxide output 
(VCO2) were evaluated continuously. V-slope method was used to detect the 
anaerobic threshold (AT). We analyzed gas exchange, Borg dyspnea index (with 6 
representing no exertion and 20 maximal exertion) [27] and changes in WHO-FC 
after 3 and 15 weeks. Health related quality of life was measured by the Short Form 
Health Survey (SF-36) [28] questionnaire at baseline and was compared to the 
results after 15 weeks. Serum N-terminal pro brain natriuretic peptide (NTproBNP) 
was obtained at baseline and after 3 and 15 weeks. 6MWD, SF-36-questionnaire and 
NT-proBNP have been obtained and analyzed by investigators who have been 
blinded to clinical data of the patients.  
 
Exercise Training Program 
Exercise training was started in-hospital during 3 weeks in the rehabilitation clinic 
Königstuhl in Heidelberg as previously described [17, 19]. We performed a program 
especially developed for the PH-patients with at least 1.5 h exercise training per day 
(in intervals distributed over the day) consisting of interval bicycle ergometer training 
at low workloads (10-60 Watt) at 7 days a week. Furthermore walking, dumbbell-
training of single muscle groups using low weights (500-1000g) and respiratory 
training were performed at 5 days per week. Maximum heart rate during the training 
corresponded to 60-80% of the heart rate reached during cardiopulmonary exercise 
testing and was monitored throughout to adjust the training intensity. Those patients 
who needed oxygen therapy already at rest remained on supplemental oxygen 
throughout the whole training program. Exercise training was closely supervised by 
physical therapists, physicians specialized in rehabilitation medicine and PH-experts 
and was continued at home for 12 weeks using an individualized training manual for 
at least 30 minutes per day at 5 days a week and a bicycle ergometer. Beside the 
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physical training all participants received mental training to improve their perception 
of individual physical abilities and limits. They were also offered psychological 
support. Adverse events were recorded whenever they occurred.  
 
Follow-up Assessment  
In 2011 all participating patients were interviewed by telephone or at a control visit in 
the Thoraxclinic Heidelberg using a half-structured questionnaire. The patients were 
asked for symptoms according to WHO functional classification, current medication, if 
and what kind of exercise training they pursued at home, for any adverse events of 
exercise training and any further cardiac events that have occurred since last 
observation. If the index patient was deceased, date of death was recorded and their 
relatives and/or treating physicians were asked for the cause and circumstances of 
death. 
 
Statistical Methods 
The analyses were performed by a statistician (C.F.). Data are given as mean ± 
standard deviation and as median, 25% and 75% quantiles for more detailed 
description at baseline. The inner-group comparisons of baseline, weeks 3 and 15 for 
6MWD, workload, Borg dyspnea index, parameters of gas exchange, PASP, 
systemic blood pressure, NT-proBNP and heart rate were conducted by Wilcoxon 
signed rank test. Also summation and subscores of the SF-36 questionnaire were 
compared by Wilcoxon rank test. WHO-FC comparisons at different time points were 
performed by McNemar-Bowden test. All tests were two sided and p-values <0.05 
were considered statistically significant. Bonferroni adjustment for multiple 
comparisons was performed for comparisons of the primary endpoints such as 
parameters of quality of life and 6-minute walking distances. All analyses were 
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carried out with IBM SPSS V20 (IBM Corp. Armonk, NY, USA). We described the 5 
patients who did not attend the 15 week measurement in detail. For missing values 
we performed different imputation strategies and reported the values from the most 
strict one: 1. multiple imputation using the MCMC method as implemented in SPSS, 
2. the last observation carried forward, and 3. a pessimistic imputation, in which 3 
week 6MWD was imputed as 15 week measurement if it was lower than baseline, 
otherwise the baseline 6MWD. Kaplan-Meier estimates have been used for survival-
analysis with asymptotic 95% two-sided confidence interval (CI) calculated from 
Greenwood’s formula. All treated patients were used for the survival analysis. 
Patients with deaths were counted as endpoints, survivors were regarded as 
censored. 
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Results 
Study Population (Table 1) 
The study group consisted of 20 patients. None of the patients had additional Down 
syndrome. Demographic data, diagnosis, functional class, hemodynamic values, lung 
function and medical therapy of the study population are summarized in table 1. Most 
patients had combined cardiac anomalies. CHD included 9 patients with ventricle 
septal defect (VSD), 6 patients with atrial septal defect (ASD), 3 patients with ASD 
and VSD, 5 patients with persistent ductus arteriosus (PDA) (3 of them combined 
with ASD,VSD and/or PFO) and 2 patients with persistent foramen ovale (PFO). ES 
was diagnosed in 10 of the 20 patients (50%); 9 patients had been operated years 
before inclusion into the study (3 VSD patch-closures, 3 ASD-closures, 2 ductus 
arteriosus-closures and 1 VSD-ASD-closure), whereas in 2 cases a relapse of the 
septal defect occurred. In all 20 patients severe APAH had been persistent or 
developed despite heart surgery. The size of the septal defect was not exactly 
assessed in every patient, but varied in those being sized from 0.5 cm to 2.5 cm. 
Further additional cardiac anomalies were a common arterial trunk (n=1), a 
hypoplastic pulmonary artery with major aortopulmonary collateral arteries and 
tricuspid insufficiency (n=1), tricuspid insufficiency in addition to the VSD (n=2), 
severe insufficiency of the pulmonary valve (n=1) and a Scimitar syndrome, an 
anomalous pulmonary venous return and dextrocardia in one patient. 
At baseline 6 patients (30%) were in WHO-FC II and 14 patients (70%) were 
classified in WHO-FC III. Fourteen patients (70%) were treated with an endothelin-
receptor-antagonist, 12 (60%) with a phosphodiesterase- inhibitor and 6 (30%) with 
inhalative or intravenous prostacyclin. Combination therapies, including 2 to 3 PAH-
targeted drugs, were used in 55% of patients (Table 1). Eleven patients received 
supplement oxygen. Cardiac catheterization showed a severe APAH with mean 
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pulmonary arterial pressures (mPAP) of 60 (±23) mmHg and a mean pulmonary 
vascular resistance (PVR) of 855 (±445) dyn*sec*cm-5.   
 
Assessment of training effects  
Exercise training significantly improved mean 6MWD by 63±47 meters after 3 weeks 
(p<0.001) and by 67±59 meters after 15 weeks (p=0.001) (Figure 1, Table 2). All 
except two patients improved in 6MWD (Figure 1) about more than 5% compared to 
baseline. The reason for non-response to exercise training in 2 of the 20 patients was 
in one patient that she could not perform most parts of the rehabilitation program due 
to a long-lasting respiratory infection. However, she improved in oxygen uptake and 
quality of life parameters. The other patient had no significant improvement in 6MWD 
although she participated in the complete program. After cardiac surgery she had 
been suffering from a chronic thoracic pain syndrome before she participated in the 
rehabilitation program.  
Exercise training also significantly improved the mean maximal workload during 
cardiopulmonary exercise testing from baseline to 3 weeks (p<0.012) and to 15 
weeks (p<0.003, Table 2). Mean peak oxygen uptake (peak VO2, Figure 2), as well 
as peak VO2/kg per kg body weight increased in trend after 3 weeks (p=0.066 and 
p=0.063) and significantly after 15 weeks (p=0.002 and p=0.008, respectively, table 
2). Mean maximal workload during cardiopulmonary exercise testing increased 
significantly after 3 and 15 weeks whereas Borg scales remained unchanged (Table 
2, Figure 3).  
SF-36 quality of life parameters were significantly impaired compared to an 
assessment of German standard population (Figure 4). Scores did not significantly 
improve by exercise training except in one subscale “bodily pain” with borderline 
significant improvement (p=0.05, Figure 4).  
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Although in 5 patients WHO-FC has improved from III to II, the change in WHO-FC 
compared to baseline after 3 and 15 weeks was not significant, possibly due to the 
small sample size (p=0.157). Mean NTproBNP serum-levels slightly decreased after 
3 weeks of exercise training and significantly increased after 15 weeks (Table 2). 
Mean oxygen saturation was reduced at rest (93±5%), decreased during 
cardiopulmonay exercise test (84±10%), and remained unchanged during 3 and 15 
weeks of exercise training (Table 2). The other parameters as mean systolic and 
diastolic systemic blood pressures and oxygen pulse remained unchanged. 
 
Missing values, results of imputation role 
Five patients (25%) did not attend the visit after 15 weeks (all referred from other PH-
centers than Heidelberg) mainly due to the long travel distance, but were reached 
during the follow-up assessment after 22±14 months. Results remained significant 
after imputation of missing values for the 6 MWD at 15 weeks using multiple 
imputations rules as described in the methods. Multiple imputation revealed a mean 
improvement of 6 MWD at 15 weeks of 67.2±50.6, p<0.001; last observation carried 
forward strategy 60.9±51.9 meters, p<0.001, and the pessimistic strategy of baseline 
observation carried forward 50.3±58.4 meters, p<0.001. The SF-36 subscore pain 
scale was significantly better after 15 Weeks, p=0.017. Comparing all variables at 
baseline and after 3 weeks the 5 patients who missed the visit after 15 weeks did not 
significantly differ from the other 15 patients. Dropouts had a similar mean age and 
improved with their 6MWD after 3 weeks (Figure 1). According to the statistical 
analysis it is unlikely that drop outs did not come to the visit after 15 weeks due to a 
reduced effect of the exercise training.  
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Worsening events during follow-up and survival 
Follow-up data were obtained after a mean period of 21±14 months (Figure 5).  
The 1-and 2- years- overall-survival rate was 100%. After 3 years 95% of our patients 
were still alive. One patient, aged 23 years, died due to right heart decompensation 
in a severe acute respiratory infection 2.5 years after rehabilitation. A female 65- 
years old patient received double-lung transplantation 14 months after exercise 
training due to disease progression. After transplantation her clinical status rapidly 
improved. Therefore, transplant-free survival rate after 1 year was 100%, after 2 
years 93%. Overall during the follow-up period 12 worsening events were noticed: 1 
patient died, 1 lung transplantation, 6 patients required in-hospital treatment 
(because of pneumonia, hysterectomy, arrhythmia and orthopedic problems). In 1 
patient an additional PAH-targeted drug was started due to clinical worsening. In 3 
patients WHO-FC had worsened from II to III.  
In 18 of the 20 patients information on the exercise training program at home could 
be obtained. All reported to continue at least some parts of the exercise training 
program, 74% had continued with walking and dumbbell-training, 68% bicycle 
ergometer training and 58% respiratory training. Two patients performed additional 
outdoor bicycle training. Sixty-five percent of patients reported to practice exercise 
training at least 3 days per week, 50% almost every day.  
 
Adverse events and non-responders 
During the 3-weeks in-hospital training 4 patients had adverse events and suffered 
from respiratory infections; 2 patients received an antibiotic therapy. Three of the 4 
patients were able to continue the training program after one or two weeks. In one 
patient the respiratory infection was long-lasting, so that she could not perform 
effective exercise training over several weeks. None of the patients had signs of 
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clinical worsening of heart failure or cyanosis during the in-hospital program. All 
patients tolerated exercise training well without severe adverse events, especially no 
syncope or presyncope occurred. Every patient reported that exercise training 
improved the awareness of physical abilities and limitations and was overall satisfied 
with the 3-weeks in-hospital program. 
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Discussion  
This is the first prospective clinical trial investigating short- and long-term effects of 
exercise training as add-on to PAH-targeted medication in patients with severe CHD-
APAH. The results of the study suggest that exercise training can significantly 
improve exercise capacity and oxygen consumption in this condition and has an 
excellent long-term overall-survival of 100% after 2 years and 95% after 3 years.  
The results represent an important source of data on survival and exercise capacity 
in patients with CHD-APAH treated by exercise training. Mean 6MWD significantly 
improved by almost 16%, mean peak oxygen consumption by ≈11%, and mean 
maximal workload by ≈29% during 15 weeks intensive exercise training program. The 
positive effect of exercise training was also documented by the feed-back of 18 
patients who continued the program at home during the follow-up period of 21±14 
months. However, these data must be confirmed in further randomized, controlled 
studies.  
 
Assessment of efficacy parameters and setting of exercise training in CHD 
The results of this study are in line with previous studies of exercise training in 
patients with other forms of PH/PAH [17-20]. These studies showed similar effects in 
patients with various forms of PH and right heart insufficiency in a randomized 
controlled [17] and in a single-arm, non-controlled design [18-20]. However, in these 
studies only few patients with CHD-APAH have been included [17, 19, 20]. Thus, 
there are almost no previous data on the effect of exercise training in patients with 
CHD-APAH. The promising results of this study suggest that in experienced hands 
exercise training may be an important add-on therapy for these patients especially in 
regard of their impaired exercise capacity and peak VO2.  
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The data of this study support previous findings in CHD-patients without PAH. Dua et 
al. reported improved exercise capacity and quality of life by regular walking training 
in 61 CHD- patients [21]. Winter et al. showed that step aerobics 3 times per week 
improved peak VO2 in 28 patients with transposition of the great arteries WHO-FC II. 
[23]. There is only one previous study with CHD-APAH showing an improved oxygen 
saturation and WHO-FC by exercise training in 4 patients [24] using an out-patient 
program twice a week.  
The effects of training may vary between different programs and settings, the results 
of our study suggest that it can improve clinically relevant parameters. However, an 
in-hospital start of the rehabilitation program has the advantage of a closely 
supervised setting which might be beneficial especially in patients with CHD-APAH, 
since they tend to overestimate their exercise capacity [29] and show severe 
hypoxemia during exercise. A profound understanding of the pathophysiology of the 
underlying cardiac anomaly on the part of the trainers and the treating physicians is 
deeply required. 
 
Improvement in 6-Minute walking distance and peak oxygen uptake 
It is well established that patients with CHD, especially those developing pulmonary 
hypertension and ES have limitation of their exercise capacity [30]. Patients with ES 
had the most impaired exercise capacity compared to other cyanotic patients [7]. 
Reduced peak VO2 and 6MWD were the main predictors of mortality in patients with 
CHD-APAH [30]. Therefore, improvement of 6MWD and peak VO2 by exercise 
training as reached in this study might be of prognostic relevance. In this study we 
show for the first time that CHD-APAH patients can improve their peak VO2 by 
exercise training although severe hypoxemia occurred in all patients during the 
program.  
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Quality of life parameters 
Although patients with CHD are severely affected with reduced exercise capacity 
especially in psychosocial aspects quality of life parameters seem to be less impaired 
as in IPAH-patients [29]. This might be due to the fact that CHD-patients live with the 
disease from childhood on and might be better adapted to exercise limitations [31]. In 
our study only the SF-36 subscale “bodily pain” improved in trend by exercise training 
although exercise capacity and peak VO2 markedly improved. Possibly in this 
disease general questionnaires such as the SF-36 are not completely appropriate. 
Previous studies found that quality of life parameters in ES-patients were mainly 
reduced in physical scales [7]. 
 
Survival rate 
Adults with CHD-APAH seem to have a better survival than those with IPAH [9]. This 
might be due to a slower progression of CHD-APAH [31] and to an almost normal 
cardiac output resulting from associating shunts. Hopkins et al. reported a survival 
rate of 89% at 2 years and 77% at 3 years in patients with CHD-APAH [9]. The 
development of ES increased mortality about 10- to 12-fold [32] and was estimated 
by 20.6% in 5 years [4]. Lowe et al. showed in a retrospective cohort study that the 
diagnosis of P(A)H in CHD increased mortality rate more than 2-fold. Heart failure 
and arrhythmia occurred 3-fold more often in CHD-APAH than in CHD-patients 
without P(A)H [8]. Compared to the previous reported survival rates [4, 9, 32] and 
considering the severely impaired hemodynamic compromise of the patients 
assessed in this study the documented overall 2-year survival rate of 100% and 
transplantation-free 2-year survival rate of 93% suggest that exercise training did at 
least not reduce but rather improve clinical worsening and long-term survival. 
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However, for further assessment of long-term effects further randomized, controlled 
trials in a larger patient population are needed.  
 
Adverse events and non-responder  
Although no severe adverse effects occurred during the in-hospital exercise training 
program of this study, in our opinion those programs should be closely monitored by 
PH-experts. Exercise training in CHD-APAH seems to be an effective add-on therapy 
but it is not completely harmless. During exercise training severe deterioration of 
oxygen saturation occurred in almost all patients. In addition the severely impaired 
right heart function needed to be monitored. Especially exercise training in patients 
with CHD-APAH has to address special needs and pathophysiological 
circumstances.  
 
Limitations 
The results of this prospective study are limited by the small number of patients with 
CHD-APAH and the lack of randomization. Because of this, there could be a referral 
bias that patients doing well have been selected. Nevertheless, the study provides a 
good rationale for future randomized-controlled studies. The effects of exercise 
training after 15 weeks may be further biased due to the missing values of 25% of 
patients who did not perform the last follow-up visit. However, the efficacy after 3 
weeks exercise and respiratory therapy and the high proportion of patients who 
continued with the program suggest a positive effect in this cohort. The significant 
effect and high compliance of exercise training in CHD-APAH-patients might also be 
due to the closely supervised in-hospital rehabilitation program, which probably 
cannot be simply translated to an out-patient program. This limits the application of 
this program in other countries which cannot provide in-hospital rehabilitation care. 
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Therefore, further studies are necessary using ambulatory training programs. 
Furthermore, it is a general problem of rehabilitation programs that the therapy 
cannot be performed double-blinded. Further prospective, randomized studies are 
necessary to determine the effects of training programs on long-term outcome in 
patients with CHD-APAH.  
 
Conclusion 
This is the first trial investigating short- and long-term effects of exercise training in 
CHD-APAH as add-on to optimized medical therapy. The results indicate that 
exercise training is effective in CHD-APAH and may improve work capacity, quality of 
life and further prognostic relevant parameters. Exercise training possibly improves 
survival rate. Further randomized studies are needed to confirm these promising 
results. 
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 Figure Legend 
Figure 1: Individual changes in Six-Minute-Walking Distance (6MWD) after 3 and 15 
weeks exercise training. With the use of Wilcoxon Test according to baseline walking 
distance, p<0.001 was obtained for the comparison to baseline with week 3 and p=0.001 
with week 15. For the analysis after 3 weeks of exercise training the data from 20 
patients, after 15 weeks of 15 patients were available and included. The coloured line 
indicates the mean change from baseline in 6MWD (63 meters and 67 meters).  
Figure 2: Peak oxygen uptake (peak VO2) at three time points. The figure represents 
significant improvements after 3 and 15 weeks exercise training (p= 0.063 and p=0.002).  
Peak VO2 increased continuously in mean change from 831±220 to 902±267 after 3 
weeks (n=16) and to 925±264 ml/min after 15 weeks (n=14). Minimum and maximum are 
indicated. 
Figure 3: Workload compared to Borg Scale. The figure shows an increase in 
workload after 3 and 15 weeks (p=0.012 and p=0.003) without significant change in Borg 
Scale (p=0.964 and p=0.877, respectively). Both are indicated as median and statistical 
minimum and maximum. The coloured columns represent workload (measured in Watt) 
and the dotted line Borg Scale. 
Figure 4: Mean SF-36 scores of Quality of life Subscales (SF-36 questionnaire) 
before and after Exercise Training. The figure shows no significant differences in 
quality of life, but in the subscale “pain” with p=0.05 after 15 weeks. The dotted line 
represents the quality of life of a healthy standard population.    
Figure 5: One- and 2-year Survival Rate.  
Within a follow-up period of 21±14 months 1 patient died and 1 patient received a lung-
transplantation. Thus, the 1-year and 2-year overall survival rate was 100%. The 
transplantation-free survival after 2 years was 93%. The dashed lines represent the 95th 
percentile of the overall- and transplantation- free survival rates. 
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Table 1: Baseline Characteristics
median
Quantile [25‐
75%]
Patients [n] 20
Gender [male/female] 4 / 16
Age [years] 48 ± 11 48 41‐55
Height [cm] 166 ± 8 165 160‐171
Weight [kg] 74 ± 18 73 62‐85
WHO functional Class ‐ No. [%]
II 6 30%
III 14 70%
Mean 6MWD [meters] 423 ± 90
Differential Diagnosis
Atrial septal defect (ASD) 9
Ventricle septal defect (VSD) 12
Kombination ASD+VSD 3
Open Foramen Ovale 2
Persistent Ductus Arteriosus (3 of them in 
combination with ASD and/or VSD) 5
Eisenmenger Reaction 10
Cardiac Catheterization
mPAP [mmHg] 60 ± 23 55 45‐84
PVR [dyn x sec x cm ‐5] 855 ± 445 776 505‐1210
RA pressure [mmHg] 6 ± 5 5 3‐9
SaO2 [%] 86 ± 13 89 80‐91
PCWP [mmHg] 10 ± 7 8 6‐12
CI [L/min/m2] 2.9 ± 0.7 2.9 2.2‐3.2
PAH‐targeted medication
Endothelin Receptor Antagonist 14 70%
Phosphodiesterase‐5‐Inhibitor 12 60%
Prostanoids inhaled 4 20%
Prostanoids intravenous 1 5%
Calcium Channel Blockers 1 5%
Combination therapy
Monotherapy 9 45%
Dualtherapy 8 40%
Tripletherapy 3 15%
Values are given as mean ± SD, 25 and 75 Quantiles [Quantile 25‐75%] or as n and %.
mPAP = mean pulmonary arterial pressure, PVR = pulmonary vascular resistance, 
RA = right atrium, SaO2 = arterial oxygen saturation, PCWP = pulmonary capillary 
wedge pressure, CI = Cardiac Index.
 Table 2: Efficacy parameters  
6MWD
Walking distance [meters]     423 ± 90 486 ± 93 486 ± 102
mean change [meters]           63 ± 47 <0.001 * 67 ± 59 <0.001 *
41 - 85 35  - 99
Quality of life Questionnaire SF-36
Physical functioning 41.2 ± 23 45.0 ± 19.4 0.206
Role-physical 45.8 ± 40 45.3 ± 42 0.631
Bodily pain 62.2 ± 33 82.4 ± 20 0.05 *
General health perception 40.6 ± 15 43.3 ± 11 0.362
Vitality 50.3 ± 20 53.8 ± 14 0.431
Social functioning 75.0 ± 24 80.8 ± 21 0.842
Role-emotional 70.4 ± 43 81.3 ± 36 0.194
Mental Health 73.6 ± 13 72.2 ± 11 0.713
Cardiopulmonary exercise testing
peak VO2/kg [mL/Min/kg] 11.4 ± 2.2 12.4 ± 2.2 0.066 12.3 ± 2.4 0.008 *
peak VO2 [mL/min] 831 ± 220 902 ± 267 0.063 925 ± 264 0.002 *
EqCO2 at AT [mL/min] 42.2 ± 10.3 43.9 ± 12.3 0.116 44.3 ± 11.6 0.285
VO2 at AT [mL/min] 683 ± 208 665 ± 203 0.271 777 ± 196 1.00
O2-pulse [(mL/min)/min-1] 7.0 ± 2.0 7.2 ± 2.1 0.345 6.8 ± 2.1 0.08
HR rest [min-1] 81 ± 15 79 ± 13 0.064 87 ± 18 0.065
HR max [min-1] 119 ± 18 122 ± 24 0.155 138 ± 15 0.004 *
RR sys rest [mmHg] 114 ± 14 115 ± 15 0.598 115 ± 12 0.687
RR dia rest [mmHg] 75 ± 9 73 ± 9 0.109 74 ± 8 0.951
RR sys max [mmHg] 140 ± 16 141 ± 21 0.552 150 ± 25 0.061
RR dia max [mmHg] 80 ± 12 83 ± 12 0.305 86 ± 11 0.116
Oxygen saturation rest [%] 92 ± 6 93 ± 4.4 0.704 93 ± 4.3 0.193
Oxygen saturation max [%] 83 ± 9.7 84 ± 10.6 0.461 83 ± 9.9 0.723
sPAP rest [mmHg] 71 ± 28 66 ± 28 0.553 60 ± 29 0.202
sPAP max [mmHg] 106 ± 30 105 ± 28 0.285 99 ± 26 0.799
Workload max [Watt] 58 ± 20 72 ± 28 0.012 # 75 ± 23 0.003 *
Borg Scale 16 ± 2 16 ± 3 0.964 16 ± 2 0.877
Laboratory parameters
NT-proBNP [pg/mL] 493 ± 471 450 ± 397 0.981 651 ± 565 0.031 #
Values are mean±SD; #p<0.05; *p<0.01 in comparison to baseline, p-values are the same for absolute values and
differences; CI = confidence interval 6MWD: two-sided Student t-test, Cardiopulmonary Exercise Testing: Wilcoxon
6-MWD = 6-minute walking distance, VO2/kg = max.oxygen consumption/kg, HR = heart rate, RR = Blood pressure 
sPAP = systolic Pulmonary arterial pressure;
Characteristic Baseline (n=20)    3 weeks (n=20) p-value p-value15 weeks (n=15)
 95% CI for the difference to baseline
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